Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Overall I like this deal for Pfizer and I imagine they will continue to invest heavily in building out the clinical programs for Metseras portfolio beyond obesity, both to help stem revenue loss from LOEs of ELIQUIS and eventually leverage that commercial footprint towards its budding obesity portfolio.
21 Prior to approval of injectable semaglutide (Wegovy) and injectable liraglutide (Saxenda) for weight loss, alternative dose formulations of injectable and oral semaglutide (Ozempic and Rybelsus) and injectable liraglutide (Victoza) were approved to treat elevated blood glucose in T2DM
The Pan African medical journal
For some, the cost is far out of reach and insurance companies aren't tripping over themselves to cover the meds
Symptoms of very low blood sugar, such as dizziness, confusion, or shakiness
US$ 20.12
US$ 24.60
US$ 24.43
&srotate=0)
US$ 27.60
